Urogen Pharma Competitors and Similar CompaniesClear all
Urogen Pharma's competitors and similar companies include LadRx and Fennec Pharma.
 LadRx LadRx Corporation (formerly known as CytRx Corporation) is a biopharmaceutical company focused on discovering, developing and commercializing new therapeutics to treat patients with cancer. |  Fennec Pharma Fennec Pharmaceuticals is a biotechnology company focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients. | ||
Founding Date | Founding Date 2004 | Founding Date 1985 | Founding Date 1996 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations New York, US HQ Tel Aviv Yafo, IL Princeton, US | Locations Los Angeles, US HQ | Locations US HQ |
Employees | Employees 194362% increase | Employees 385% decrease | Employees 433% increase |
Valuation ($) | Valuation ($) 515.9 m | Valuation ($) 901.1 k | Valuation ($) 129.4 m |
Financial | |||
Revenue (est.) | Revenue (est.) $109.8m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $44.6m (FY, 2025) |
Net income | Net income ($153.5m) (FY, 2025) | Net income ($1.6m) (FY, 2024) | Net income ($9.7m) (FY, 2025) |
For sources of this data, please see the company profile
View Company Profiles
LadRx
HQ
Los Angeles, US
Employees
3
LadRx Corporation (formerly known as CytRx Corporation) is a biopharmaceutical company focused on discovering, developing and commercializing new therapeutics to treat patients with cancer.
View companyFennec Pharma
HQ
US
Employees
4↑ 33% increase
Fennec Pharmaceuticals is a biotechnology company focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients.
View company